BioWorld

Dec. 15, 2008

Exelixis Getting $195M Up Front in BMS Cancer Collaboration

Exelixis signed a major deal with Bristol-Myers Squibb Co., in which the drugmaker would pay a hefty $195 million up front for rights to cancer programs developed by Exelixis. (BioWorld Today) Read More

Daschle to Lead HHS, White House Health Reform Office

Momenta's Offering Adds $25M as FOBs Gain Momentum

BioPartnering: Learn How to Make the Right Moves

Vivus' Avanafil Starts Pivotal Testing in Erectile Dysfunction

Disappointing Memory Data Send Lexicon Shares Sliding

Other News To Note

Clinic Roundup

CTRC-AACR Roundup

Today's news in brief

BioWorld

BioWorld briefs for Dec. 12, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 12, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Illustration of brain with electrical activity background

ABS-1230 controls seizures in KCNT1-driven severe epilepsy

BioWorld Science

Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...

Illustration of head with maze that is missing parts

CTAD 2025: The challenges of combination therapies for dementia

BioWorld Science

At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...